Amylyx Pharmaceuticals IncNASDAQ:AMLX
- LAST PRICE3.1350
- TODAY'S CHANGE (%)0.0150 (0.4808%)
- Bid / Lots3.1300/ 6
- Ask / Lots3.1400/ 13
- Open / Previous Close3.1300 / 3.1200
- Day Range
- 52 Week Range
- Volume485,789
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMLX |
|---|---|---|
| 09:32 ET | 15985 | 3.15 |
| 09:34 ET | 5671 | 3.12 |
| 09:36 ET | 4721 | 3.175 |
| 09:38 ET | 2820 | 3.2 |
| 09:39 ET | 9310 | 3.2008 |
| 09:41 ET | 5783 | 3.1901 |
| 09:43 ET | 1678 | 3.1981 |
| 09:45 ET | 5150 | 3.2012 |
| 09:48 ET | 3561 | 3.2001 |
| 09:50 ET | 1990 | 3.19 |
| 09:52 ET | 18337 | 3.2 |
| 09:54 ET | 11586 | 3.2099 |
| 09:56 ET | 4322 | 3.185 |
| 09:57 ET | 12709 | 3.2088 |
| 09:59 ET | 4673 | 3.205 |
| 10:01 ET | 1000 | 3.205 |
| 10:03 ET | 1619 | 3.201 |
| 10:06 ET | 2671 | 3.211 |
| 10:08 ET | 1200 | 3.205 |
| 10:12 ET | 350 | 3.205 |
| 10:14 ET | 1362 | 3.2012 |
| 10:15 ET | 5167 | 3.18 |
| 10:17 ET | 4090 | 3.185 |
| 10:19 ET | 500 | 3.185 |
| 10:21 ET | 600 | 3.185 |
| 10:24 ET | 3051 | 3.17 |
| 10:26 ET | 1193 | 3.165 |
| 10:28 ET | 2152 | 3.165 |
| 10:30 ET | 1240 | 3.1545 |
| 10:32 ET | 12007 | 3.17 |
| 10:33 ET | 2531 | 3.161 |
| 10:35 ET | 226 | 3.165 |
| 10:37 ET | 200 | 3.165 |
| 10:42 ET | 226 | 3.165 |
| 10:44 ET | 18946 | 3.1491 |
| 10:46 ET | 1952 | 3.145 |
| 10:48 ET | 3934 | 3.154 |
| 10:50 ET | 7121 | 3.15 |
| 10:51 ET | 38003 | 3.125 |
| 10:53 ET | 1266 | 3.1201 |
| 10:55 ET | 4786 | 3.105 |
| 10:57 ET | 5798 | 3.105 |
| 11:00 ET | 1303 | 3.105 |
| 11:02 ET | 2115 | 3.102 |
| 11:04 ET | 400 | 3.105 |
| 11:06 ET | 3602 | 3.115 |
| 11:08 ET | 6098 | 3.115 |
| 11:09 ET | 413 | 3.115 |
| 11:11 ET | 913 | 3.125 |
| 11:13 ET | 458 | 3.1219 |
| 11:15 ET | 1521 | 3.125 |
| 11:18 ET | 200 | 3.125 |
| 11:20 ET | 8270 | 3.125 |
| 11:22 ET | 6555 | 3.115 |
| 11:24 ET | 5993 | 3.14 |
| 11:26 ET | 3460 | 3.135 |
| 11:27 ET | 1100 | 3.125 |
| 11:29 ET | 158 | 3.125 |
| 11:31 ET | 2568 | 3.13 |
| 11:36 ET | 805 | 3.1201 |
| 11:38 ET | 1100 | 3.1297 |
| 11:40 ET | 13434 | 3.115 |
| 11:42 ET | 3344 | 3.105 |
| 11:44 ET | 1814 | 3.101 |
| 11:45 ET | 12739 | 3.115 |
| 11:47 ET | 2879 | 3.125 |
| 11:49 ET | 796 | 3.125 |
| 11:51 ET | 11850 | 3.12 |
| 11:54 ET | 5151 | 3.145 |
| 11:56 ET | 848 | 3.15 |
| 11:58 ET | 743 | 3.145 |
| 12:00 ET | 648 | 3.145 |
| 12:02 ET | 4899 | 3.15 |
| 12:03 ET | 1500 | 3.155 |
| 12:05 ET | 8917 | 3.1511 |
| 12:07 ET | 1700 | 3.1589 |
| 12:09 ET | 9427 | 3.175 |
| 12:12 ET | 18853 | 3.21 |
| 12:14 ET | 4918 | 3.195 |
| 12:16 ET | 1200 | 3.19 |
| 12:18 ET | 200 | 3.185 |
| 12:21 ET | 2296 | 3.17 |
| 12:23 ET | 1736 | 3.1701 |
| 12:25 ET | 509 | 3.175 |
| 12:30 ET | 657 | 3.175 |
| 12:32 ET | 2534 | 3.18 |
| 12:34 ET | 3391 | 3.18 |
| 12:36 ET | 774 | 3.175 |
| 12:41 ET | 300 | 3.175 |
| 12:43 ET | 1200 | 3.165 |
| 12:45 ET | 100 | 3.16 |
| 12:48 ET | 200 | 3.165 |
| 12:50 ET | 2400 | 3.165 |
| 12:52 ET | 1374 | 3.165 |
| 12:54 ET | 5380 | 3.155 |
| 12:57 ET | 100 | 3.155 |
| 12:59 ET | 100 | 3.155 |
| 01:01 ET | 1484 | 3.155 |
| 01:03 ET | 979 | 3.1589 |
| 01:06 ET | 458 | 3.16 |
| 01:08 ET | 2089 | 3.155 |
| 01:10 ET | 900 | 3.155 |
| 01:12 ET | 2100 | 3.155 |
| 01:14 ET | 642 | 3.155 |
| 01:15 ET | 1046 | 3.155 |
| 01:17 ET | 2300 | 3.155 |
| 01:19 ET | 3319 | 3.145 |
| 01:21 ET | 5323 | 3.135 |
| 01:24 ET | 100 | 3.135 |
| 01:28 ET | 100 | 3.135 |
| 01:30 ET | 21246 | 3.135 |
| 01:32 ET | 100 | 3.135 |
Sep 16, 2024
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm, from 11:42AM ET on Monday Sep 16, 2024 by Dow Jones
11:42AM ET on Monday Sep 16, 2024 by Dow Jones
Aug 28, 2024
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences, from 8:30AM ET on Wednesday Aug 28, 2024 by Dow Jones
8:30AM ET on Wednesday Aug 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amylyx Pharmaceuticals Inc | 212.4M | -1.3x | --- |
Organogenesis Holdings Inc | 367.2M | -22.5x | --- |
Amarin Corporation PLC | 233.0M | -7.0x | --- |
Ironwood Pharmaceuticals Inc | 627.8M | 93.0x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Coherus BioSciences Inc | 114.2M | -2.6x | --- |
Company Information
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Contact Information
- Headquarters
- 43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141
- Phone
- 617-682-0917
- Fax
- 302-636-5454
Executives
- Chair of the Board of Directors
- George Milne
- Co-Chief Executive Officer, Director
- Joshua Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Chief Financial Officer
- James Frates
- Chief Legal Officer and General Counsel
- Gina Mazzariello
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $212.4M |
|---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
